Save time and get answers to complex questions with AI chat
Adefovir dipivoxil discount cardIs liver function monitoring necessary with lipitorEnhertu loss of exclusivity patent expirationOzempic jordan price 2026Nicardipine brand names
See the DrugPatentWatch profile for Saphnelo
Yes. Saphnelo (anifrolumab) is used to treat certain people with moderate to severe systemic lupus erythematosus (SLE). It targets type I interferon signaling, which is part of the inflammatory pathway in lupus. [1]
Saphnelo is indicated for systemic lupus erythematosus (SLE), not discoid lupus. It is intended for patients with active disease where treatment with other therapies may not fully control symptoms. [1]
Saphnelo is given as an intravenous infusion in a clinical setting. [1]
Common safety concerns for lupus biologics include risks related to immune effects, such as infections; patients generally need monitoring and should report fever or signs of infection promptly. [1]
[1] https://www.drugpatentwatch.com/
Other Questions About Saphnelo :